BackEucrates Biomedical Acquisition Overview
Eucrates Biomedical Acquisition Corp

Eucrates Biomedical Acquisition Return on Equity

Eucrates Biomedical Acquisition (EUCR) has a ROE of 63.76%, above the sector sector average of -4.47%.

Get informed when a big investor buys or sells

+ Follow

ROE

63.76%

Return on Equity

63.76%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Eucrates Biomedical Acquisition (EUCR) FAQ

As of the most recent data, EUCR shows a ROE of 63.76%. That is above the sector sector average of -4.47%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about -4.47%. Eucrates Biomedical Acquisition is at 63.76%, which is higher that average. That is roughly 1526.9% above the sector mean. Use the comparison chart on this page to see how EUCR stacks up against individual peers as well.

Check the historical chart to see whether EUCR's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Eucrates Biomedical Acquisition with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Eucrates Biomedical Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 63.76%) with ownership activity and broader fundamentals.